Nuvation Bio Inc. Share Price

Nuvation Bio Inc. Share Price

NYSE: NUVB | Micro Cap
$3.91
+$0.06 (1.56%) Last updated on 18 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Nuvation Bio Inc. Stock Performance

Open
$3.84
Prev. Close
$3.85
Circuit Range
N/A
Day Range
$3.80 - $3.98
Year Range
$3.80 - $9.75
Volume
2,71,271
Average Traded
$3.89

Nuvation Bio Inc. Share Price Today

As of 18 November 2026, Nuvation Bio Inc.'s share price is $3.91. The stock opened at $3.84, compared to its previous close of $3.85. During today's trading session, Nuvation Bio Inc.'s share price traded between $3.80 and $3.98, with an average price of $3.89. Over the past 52 weeks, the stock has recorded a high of $9.75 and a low of $3.80. In terms of performance, Nuvation Bio Inc.'s share price has declined by 18.03% over the last six months and is down 51.30% on a year-on-year basis.

Nuvation Bio Inc. Share Price Chart

Line chart of the Nuvation Bio Inc. price trend over the selected period. The price rose overall, ranging from 3.80 to 3.98, ending at 3.90.
$3.80$3.98
L
Show Current Price
H

Nuvation Bio Inc. Stock Fundamentals & Key Indicators

Market Cap
$1.34M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.39
Revenue (TTM)
$62.90B
Return On Equity (TTM)
-59.63%
Profit Margin
-325.33%
Debt to Equity
1.32
Quarterly Earnings Growth YoY
-14.51%

Nuvation Bio Inc. Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$41.87$83.23$31.69$44.95
Net Profit-$36.59$5.40-$62.84-$41.90
Net Profit Margin-87.39%6.49%-198.30%-93.21%
Income ChangeN/A114.76%-1263.70%33.32%

Nuvation Bio Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$7.87$62.90
Net Profit-$104.20-$75.80-$567.94-$204.63
Net Profit MarginN/AN/A-7216.52%-325.33%
Income ChangeN/A27.26%-649.26%63.97%

About Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Nuvation Bio Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$4.81
$3.92
-17.58%
Oct 2026
$5.60
$4.75
-15.33%
Sep 2026
$6.67
$5.61
-19.74%
Aug 2026
$6.27
$6.99
+10.34%
Jul 2026
$5.81
$6.33
+11.63%
Jun 2026
$4.75
$5.67
+18.97%
May 2026
$4.43
$4.77
+7.43%
Apr 2026
$4.40
$4.44
+3.74%
Mar 2026
$5.70
$4.28
-27.70%
Feb 2026
$5.24
$5.92
+12.55%
Jan 2026
$8.97
$5.26
-41.33%
Dec 2025
$7.92
$8.96
+11.66%

NUVB Share Price FAQs